US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker

Core Insights - BioPorto A/S is participating in the US News & World Report webinar titled "New Frontiers in Kidney Care," focusing on acute and chronic kidney disease and the importance of kidney health integration into broader health strategies [1][2] - The webinar will feature a panel discussion moderated by Shanley Chien, with speakers who have extensive experience in kidney biomarker research, particularly the NGAL biomarker [2][5] - BioPorto's flagship products utilize the NGAL biomarker to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), allowing for earlier intervention and tailored patient management strategies [6][7] Company Overview - BioPorto is an in vitro diagnostics company dedicated to improving patient outcomes through actionable kidney biomarkers, addressing significant unmet medical needs in kidney care [6][7] - The company has facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [8] Product Information - The NGAL tests developed by BioPorto are designed to identify patients at risk of AKI more rapidly than standard care measurements, which can significantly reduce morbidity and mortality associated with delayed diagnosis [7]